CN102159232A - 使用哺乳动物β防御素治疗炎性疾病 - Google Patents

使用哺乳动物β防御素治疗炎性疾病 Download PDF

Info

Publication number
CN102159232A
CN102159232A CN2009801363423A CN200980136342A CN102159232A CN 102159232 A CN102159232 A CN 102159232A CN 2009801363423 A CN2009801363423 A CN 2009801363423A CN 200980136342 A CN200980136342 A CN 200980136342A CN 102159232 A CN102159232 A CN 102159232A
Authority
CN
China
Prior art keywords
beta defensin
tnf
hbd2
disease
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801363423A
Other languages
English (en)
Chinese (zh)
Inventor
坦贾·M·R·凯尔
托马斯·克鲁泽
珀尔·H·迈金德
卡罗琳·S·布林奇
泽伦·凯拉尔夫
伯吉特·安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes Biopharma DK AS
Original Assignee
Novozymes Adenium Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41445843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102159232(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes Adenium Biotech AS filed Critical Novozymes Adenium Biotech AS
Publication of CN102159232A publication Critical patent/CN102159232A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
CN2009801363423A 2008-07-18 2009-07-17 使用哺乳动物β防御素治疗炎性疾病 Pending CN102159232A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP08160761.6 2008-07-18
EP08160761 2008-07-18
EP08162486.8 2008-08-15
EP08162486 2008-08-15
EP08163614 2008-09-03
EP08163614.4 2008-09-03
EP09160448.8 2009-05-15
EP09160448 2009-05-15
PCT/EP2009/059251 WO2010007165A2 (en) 2008-07-18 2009-07-17 Treatment of inflammatory diseases with mammal beta defensins

Publications (1)

Publication Number Publication Date
CN102159232A true CN102159232A (zh) 2011-08-17

Family

ID=41445843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801363423A Pending CN102159232A (zh) 2008-07-18 2009-07-17 使用哺乳动物β防御素治疗炎性疾病

Country Status (18)

Country Link
US (1) US20100016232A1 (https=)
EP (1) EP2320929B1 (https=)
JP (1) JP2011528332A (https=)
KR (2) KR20110031962A (https=)
CN (1) CN102159232A (https=)
AP (1) AP2011005537A0 (https=)
AR (1) AR072524A1 (https=)
AU (1) AU2009272680A1 (https=)
BR (1) BRPI0915780A2 (https=)
CA (1) CA2730674A1 (https=)
CL (1) CL2011000098A1 (https=)
EA (1) EA201170218A1 (https=)
IL (1) IL210714A0 (https=)
MX (1) MX2011000569A (https=)
NZ (1) NZ590466A (https=)
TW (1) TW201004641A (https=)
WO (1) WO2010007165A2 (https=)
ZA (1) ZA201100462B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110290799A (zh) * 2016-12-13 2019-09-27 防御素治疗学公司 用于治疗肺部炎性病症的方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232248B2 (en) * 2008-07-18 2012-07-31 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
SG172709A1 (en) 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
BR112012025844A2 (pt) 2010-04-15 2017-07-18 Marine Polymer Tech Inc uso de nanofibras snag
KR101329774B1 (ko) * 2010-06-16 2013-11-15 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
CA2832859C (en) * 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
JP6151981B2 (ja) * 2013-06-18 2017-06-21 一般社団法人健康科学リソースセンター 関節リウマチ患者における生物学的製剤の有効性の予測方法
JP2017525370A (ja) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法
GB201603653D0 (en) * 2016-03-02 2016-04-13 Cambridge Entpr Ltd Combination Therapy
CN109414474B (zh) 2016-04-29 2024-07-02 诺维信公司 肝脏、胆道和胰腺障碍的治疗
KR102631542B1 (ko) * 2018-03-14 2024-02-01 서울대학교산학협력단 염증 감소능 및 줄기세포로부터 연골세포로의 분화 촉진능을 가지는 이중 기능성 펩타이드 및 이의 용도
KR102631543B1 (ko) 2018-03-14 2024-02-01 서울대학교산학협력단 세포 투과능 및 근육 재생능을 가지는 이중 기능성 펩타이드 및 이의 용도
WO2020046002A1 (ko) * 2018-08-31 2020-03-05 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
KR102244161B1 (ko) 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
CA3249846A1 (en) 2022-01-28 2023-08-03 Kenvue Brands Llc Predictive Biomarkers for Atopic Dermatitis
KR20250025597A (ko) 2022-04-04 2025-02-24 존슨 앤드 존슨 컨수머 인코포레이티드 아토피성 피부염의 발병을 예방하거나 아토피성 피부염을 치료하기 위한 기회의 창 피부 치료 요법 및 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034820A1 (en) * 2000-11-28 2006-02-16 Lim David J Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
WO2007007116A1 (en) * 2005-07-14 2007-01-18 Ares Trading S.A Defensin proteins
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540506A (en) * 2002-12-19 2008-09-26 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
KR20100071985A (ko) * 2007-09-11 2010-06-29 몬도바이오테크 래보래토리즈 아게 치료제로서의 데펜신 펩티드의 용도
US8232248B2 (en) * 2008-07-18 2012-07-31 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
SG172709A1 (en) * 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034820A1 (en) * 2000-11-28 2006-02-16 Lim David J Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2007007116A1 (en) * 2005-07-14 2007-01-18 Ares Trading S.A Defensin proteins
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110290799A (zh) * 2016-12-13 2019-09-27 防御素治疗学公司 用于治疗肺部炎性病症的方法

Also Published As

Publication number Publication date
IL210714A0 (en) 2011-03-31
WO2010007165A3 (en) 2010-06-03
NZ590466A (en) 2012-08-31
JP2011528332A (ja) 2011-11-17
KR20110031962A (ko) 2011-03-29
AP2011005537A0 (en) 2011-02-28
CA2730674A1 (en) 2010-01-21
KR20110044863A (ko) 2011-05-02
EP2320929B1 (en) 2019-05-29
WO2010007165A2 (en) 2010-01-21
US20100016232A1 (en) 2010-01-21
ZA201100462B (en) 2013-03-27
MX2011000569A (es) 2011-02-23
EA201170218A1 (ru) 2011-08-30
AR072524A1 (es) 2010-09-01
AU2009272680A1 (en) 2010-01-21
CL2011000098A1 (es) 2011-10-07
EP2320929A2 (en) 2011-05-18
TW201004641A (en) 2010-02-01
BRPI0915780A2 (pt) 2019-03-12

Similar Documents

Publication Publication Date Title
CN102159232A (zh) 使用哺乳动物β防御素治疗炎性疾病
CN102247591A (zh) 使用哺乳动物β防御素的炎性肠病的治疗
Zaiou et al. Cathelicidins, essential gene-encoded mammalian antibiotics
US9217021B2 (en) Oral treatment of inflammatory bowel disease
EP2320928B1 (en) Treatment of rheumatoid arthritis with human beta defensins
CN102036678A (zh) 针对脑膜炎的防卫素的用途
Class et al. Patent application title: Treatment Of Rheumatoid Arthritis With Mammal Beta Defensins Inventors: Tanja Maria Rosenkilde Kjaer (Holte, DK) Tanja Maria Rosenkilde Kjaer (Holte, DK) Thomas Kruse (Copenhagen N, DK) Per Holse Mygind (Vaerloese, DK) Per Holse Mygind (Vaerloese, DK) Karoline Sidelmann Brinch (Copenhagen Nv, DK) Karoline Sidelmann Brinch (Copenhagen Nv, DK) Soeren Kjaerulff (Holte, DK) Birgitte Andersen (Bagsvaerd, DK) Birgitte Andersen (Bagsvaerd, DK) Assignees: Novozymes A/S
AU2011203033A1 (en) Treatment of inflammatory bowel diseases with mammal beta defensins
HK1164735A (en) Treatment of inflammatory bowel diseases with mammal beta defensins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110817